Integra LifeSciences Will Feature Its New EndoRelease Endoscopic Cubital Tunnel Release System At American Society for Surgery of the Hand Annual Meeting

PLAINSBORO, N.J., Sep 17, 2008 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the introduction of the EndoRelease(TM) Endoscopic Cubital Tunnel Release System. The EndoRelease(TM) System will initially be marketed in the United States and will be featured at the 63rd annual American Society for Surgery of the Hand Meeting, September 18-20, 2008 in Chicago, Illinois. The EndoRelease(TM) System was designed in conjunction with Tyson Cobb MD, Davenport, IA.

The EndoRelease(TM) Endoscopic Cubital Tunnel Release System is designed for the surgical treatment of cubital tunnel syndrome, a condition caused by entrapment of the ulnar nerve at the elbow that may result in symptoms such as numbness and/or pain in the ring and little fingers and hand weakness. Standard surgical treatment for this syndrome includes invasive open procedures such as simple decompression, anterior transposition of the nerve, and medial epicondylectomy. Recovery following these procedures often involves a period of immobilization, significant restriction on movement, and extensive therapy.

The EndoRelease(TM) System offers a new, minimally invasive approach to surgically treating cubital tunnel syndrome through a series of innovative instruments designed for safely releasing fascia surrounding the ulnar nerve. Potential benefits offered by the EndoRelease System include smaller incision, efficient and reliable surgical technique, and more rapid patient recovery.

"The EndoRelease(TM) System offers a minimally invasive approach to the treatment of cubital tunnel syndrome through a unique system of instrumentation. We are very excited about this launch as it further expands Integra's extensive line of upper extremity nerve treatment options, which include NeuraGen(R) Nerve Guide, NeuraWrap(TM) Nerve Protector, and SafeGuard (R) Mini Carpal Tunnel Release System," said Robert Paltridge, President of Integra Extremity Reconstruction. "Integra offers one of the most comprehensive lines of nerve repair, protection, and decompression products available to address the needs of orthopedic and neurosurgeons."

Cubital tunnel syndrome is the second most frequent compressive neuropathy in the upper extremity, after carpal tunnel syndrome. Cubital tunnel syndrome affects men 3-8 times as often as women and occurs most commonly in patients between 30-60 years in age.

The EndoRelease(TM) Endoscopic Cubital Tunnel Release System will be sold by Integra's eighty person Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Integra's products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. The company's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. For more information visit www.Integra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use Integra's product may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2007 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-P

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President, Finance

and Administration, and Chief Financial Officer
(609) 936-2481
jhenneman@Integra-LS.com
Gianna Sabella, Public Relations Manager
(609) 936-2389
gsabella@intergra-LS.com